

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 January 2024 (11.01.2024)



(10) International Publication Number
WO 2024/010810 A3

(51) International Patent Classification:
C07D 307/06 (2006.01) *A61P 35/00* (2006.01)
A61P 31/14 (2006.01)

Apt 1226, San Diego, CA 92122 (US). **TARI, Leslie, W.**;
13347 Kibbings Road, San Diego, CA 92130 (US).

(21) International Application Number:
PCT/US2023/026932

(74) Agent: **BELLIVEAU, Michael, J.** et al.; Clark & Elbing
LLP, 101 Federal Street, 15th Floor, Boston, MA 02110
(US).

(22) International Filing Date:
05 July 2023 (05.07.2023)

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/358,385 05 July 2022 (05.07.2022) US
63/437,093 04 January 2023 (04.01.2023) US
63/449,813 03 March 2023 (03.03.2023) US
63/522,357 21 June 2023 (21.06.2023) US

(71) Applicant: **CIDARA THERAPEUTICS, INC.** [US/US];
6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121
(US).

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(72) Inventors: **BORCHARDT, Allen**; 5419 Via Carancho,
San Diego, CA 92111 (US). **BRADY, Thomas, P.**; 7561
Windsong Road, San Diego, CA 92126 (US). **CHEN,
Hongyuan**; 17 Helmcree, Aliso Viejo, CA 92656 (US).
COLE, Jason; 17936 Myrica Lane, San Diego, CA 92127
(US). **DE, Ramkrishna**; 1215 Adobe Terrace, Vista, CA
92081 (US). **FORTIER, Joanne, M.**; 12575 Rideabout
Ct, San Diego, CA 92129 (US). **HAUSSENER, Travis,
James**; 3971 Ecochee Ave, San Diego, CA 92117 (US).
LAM, Thanh; 10865 Parkdale Ave, San Diego, CA 92126
(US). **PANICKAR, Dhanya, Raveendra**; 3445 Lebon Dr.,


Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*

(54) Title: FC CONJUGATES INCLUDING AN INHIBITOR OF CD73 AND USES THEREOF

FIG. 1A

CD73 inhibitor screen cell-free enzyme based assay



Compound	Cell-free CD73 inhibition IC ₅₀ (nM)
Conjugate 133a	8.803
Conjugate 133b	10.37
AB-680 (positive control)	1.605
Int-258 (small molecule, no Fc)	26.07

(57) Abstract: The disclosure provides conjugates including an Fc domain monomer or Fc domain covalently linked to a moiety that binds to or inhibits CD73. The disclosure also provides pharmaceutical compositions including such conjugates and uses of such conjugates in the treatment of disorders associated with dysregulation or overexpression of CD73 (e.g., cancer, fibrosis, or a viral infection).

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

28 March 2024 (28.03.2024)